Vical Incorporated today announced that it has expanded its infectious disease portfolio with the addition of a novel antifungal, ASP2397, in-licensed from Astellas Pharma Inc. . ASP2397 represents a potential new class of antifungal compounds to address invasive Aspergillus infections, which are major causes of morbidity and mortality in immunocompromised patients, including transplant recipients.
http://ift.tt/1GuLMgk
http://ift.tt/1GuLMgk
No comments:
Post a Comment